Compare

Abivax SA ADS/$ABVX

1D1W1M3M6MYTD1Y5YMAX

About Abivax SA ADS

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
Ticker
$ABVX
Sector
Health
Primary listing
NASDAQ
Employees
98
Headquarters
Paris, France
Website
www.abivax.com

Abivax SA ADS Metrics

BasicAdvanced
$7.8B
-
-$5.83
-0.25
-

What the Analysts think about Abivax SA ADS

Analyst ratings (Buy, Hold, Sell) for Abivax SA ADS stock.
Analyst projections of the future price of Abivax SA ADS stock.

Bulls say / Bears say

In the Phase 3 maintenance trial, obefazimod delivered clinical remission in about 51% of patients at both doses, versus 10.4% on placebo, and met its key secondary endpoints. That gives the drug a strong efficacy case in ulcerative colitis. (Reuters)
The FDA has agreed with Abivax on the planned content, format and submission strategy for its ulcerative colitis application. The company says it remains on track to file in the fourth quarter of 2026, a clear step towards regulatory review. (SEC)
The July share offering brought in $920 million and is expected to fund operations into the fourth quarter of 2029. This gives Abivax more scope to prepare for a potential US launch without needing near-term financing. (Abivax)
The maintenance trial reported several malignancies among patients receiving obefazimod, despite investigators considering the cancer cases unrelated to treatment. The signal has raised safety questions that could affect regulatory review and investor confidence. (The Wall Street Journal)
Abivax’s prospects remain heavily tied to obefazimod: its ulcerative colitis application is still pending, while Crohn’s disease remains in Phase 2b with results expected in mid-2027. A setback in ulcerative colitis would therefore leave no near-term, clinically validated alternative to support the investment case. (SEC)
The July equity offering raised substantial cash but diluted existing holders by about 8% on a non-diluted basis, or up to 9.2% if the underwriters’ option was exercised in full. Further equity funding could dilute shareholders again if costs or timelines exceed expectations. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 16 Oct 2026.

Abivax SA ADS Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Abivax SA ADS Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Abivax SA ADS News

AllArticlesVideos

These Analysts Slash Their Forecasts On Abivax Following H1 Results

Benzinga1 month ago

Accenture, Abivax and 3 Stocks to Watch Heading Into Monday

Benzinga1 month ago

Abivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Benzinga2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.